Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers February 22, 2018
Pharmacy Choice - News - U.S. Pharmaceutical Industry - February 22, 2018

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

2/22/18 - 200+ Demonstrators to Tell U.S. Rep. Scott Peters (D-CA) to Drop His Bill Gutting 340B Drug Discount Program
A group of more than 200 picketers concerned about an ongoing assault by the pharmaceutical industry on a drug price discount program utilized by many non-profit hospitals and community clinics to help them provide medical care and services to low-income individuals and underserved populations, are expected at a robust demonstration and picket line
2/22/18 - Aimmune Therapeutics Announces Pricing of Public Offering of Common Stock
Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $32.00 per share, for gross proceeds of $176 million before deducting estimated underwriting
2/22/18 - Another SC county sues drug companies over opioid crisis, more could follow [The State (Columbia, S.C.)]
Both Anderson and Greenville counties are considering similar action. The Greenville News reports Greenville County Council hired Spartanburg attorney John White Tuesday to investigate the grounds for filing its own suit over the crisis. In Anderson, the Independent Mail reports County Council chairman Tommy Dunn encouraged his colleagues to take..
2/22/18 - Medical Imaging Reagents Market Trends & Projection to : Rapid development across a number of technology fields promise to change the medical imaging industry by enabling novel imaging reagents and unique market opportunities.
Albany, NY 02/21/2018 Medical imaging is used to define the use of conventional and sophisticated diagnostic practices. Traditional imaging techniques like computed tomography, magnetic resonance imaging, ultrasound, X-ray, and nuclear medicine usually analyze morphology and anatomy but are unable to detect changes at the molecular level.
2/22/18 - Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2017 on Thursday, March 1, 2018, After Close of U.S.-Based Financial Markets
Nektar Therapeutics will announce its financial results for the fourth quarter and year-ended December 31, 2017, on Thursday, March 1, 2018, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/ 2:00 p.m. Pacific
2/22/18 - Portland to sue opioid companies for costs of local havoc [The Oregonian, Portland, Ore.]
Feb. 21 The city of Portland will join a national movement by suing drug companies behind America's opioid crisis. "This is a much-needed step to help stem the tide of opioid addiction in our community," Portland Mayor Ted Wheeler said. Portland will join at least 370 other cities and counties across America suing drug manufacturers or distribut
2/22/18 - Single-Use Technology for Biopharmaceuticals Market Size Will Escalate Rapidly in the Near Future: Rise in biologics and biosimilars market will ultimately rise the market for Single-use Technology for Biopharmaceuticals.
Albany, NY 02/21/2018 Single-use or disposable products or technology is intended to be used for one time only and then are meant for disposing. These technologies are mainly made from Plastic which are disposed off after use. Single-use technologies have transformed the field of biopharmaceuticals.
2/21/18 - "System and Method for Monitoring Pharmaceutical Usage" in Patent Application Approval Process (USPTO 20180032699)
By a News Reporter-Staff News Editor at Telecommunications Weekly A patent application by the inventors Carrender, Curtis L.; Morrisey, Daniel; Sainion, Soneer, filed on July 28, 2017, was made available online on February 8, 2018, according to news reporting originating from Washington, D.C., by VerticalNews correspondents. This patent applicati
2/21/18 - 'First Of Its Kind' Service Launches To Support Drug Labeling Compliance Rule
"It's the first service of its kind to aid pharmaceutical companies in this way," described Stephen Braddock, MD, a St. Louis- based pediatrician and dysmorphologist in reference to a new endeavor offered by birth defects experts at the Organization of Teratology Information Specialists. OTIS, Inc. is a wholly owned Benefit Corporation established
2/21/18 - 2018 Dengue DNA Vaccine Drug Analysis -
The "Drug Analysis: Dengue DNA vaccine" drug pipelines has been added to' s offering. The US Naval Medical Research Center is developing a Vaxfectin- adjuvanted, tetravalent plasmid DNA vaccine. In 2008, Vical entered into an agreement with the NMRC to manufacture the vaccine, but it does not currently have a license for furt
2/21/18 - AbbVie and Voyager Therapeutics Announce Global Strategic Collaboration to Develop Potential New Treatments for Alzheimer's disease
NORTH CHICAGO- AbbVie, a global biopharmaceutical company, and Voyager Therapeutics, Inc., a clinical-stage gene therapy company, today announced that they have entered into an exclusive strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed against tau for the treatment of Alzheimer's disease and..
2/21/18 - AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
AbbVie, a global research and development-based biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc., announced that the Phase 3 ELARIS UF-I study of elagolix met its primary endpoint. Uterine fibroids are the most common type of abnormal growth in a woman's pelvis and can affect up to 80 percent of women by age 50. 1 Fibro
2/21/18 - AbbVie doubles down on tau with Voyager Alzheimer`s deal [Arab News (Saudi Arabia)]
AbbVie has teamed up with Voyager Therapeutics on a tau protein-targeting program, paying $69 million upfront for an option on the Alzheimers disease candidate. According to AbbVie, that approach would have dosing advantages over current tau-targeting drugs in the industrys pipeline that could translate into a higher chance of showing efficacy.
2/21/18 - AbbVie Presents New Positive Late-Breaking Data from Two Phase 3 Psoriasis Trials of Risankizumab at the 2018 American Academy of Dermatology Annual Meeting
AbbVie presented new positive results from clinical trials that evaluated risankizumab compared to placebo or ustekinumab, at the 2018 American Academy of Dermatology Annual Meeting in San Diego.
2/21/18 - Abeona Therapeutics Announces Upcoming Conference Participation
NEW YORK and CLEVELAND, Feb. 21, 2018 Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the Company s senior management team will participate in the following investor and industry conferences..
2/21/18 - ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 27 2018
SAN DIEGO- ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2017 on Tuesday, February 27,
2/21/18 - Acceleron to Webcast Fourth Quarter and Full Year 2017 Operating and Financial Results on February 27 2018
CAMBRIDGE, Mass.- Acceleron Pharma Inc. today announced it will host a webcast and conference call on Tuesday, February 27, 2018 at 5:00 p.m. EST to discuss its fourth quarter and full year 2017 operating and financial results. Acceleron is a Cambridge- based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and...
2/21/18 - Achieve Announces Preliminary Data from Cytisine Phase I II Multi-Dose Pharmacokinetic and Pharmacodynamics Clinical Study
BOTHELL, Washington and VANCOUVER- Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced preliminary data from their Phase I/II multi-dose, pharmacokinetic and pharmacodynamics clinical study of cytisine.
2/21/18 - Acorda Therapeutics to Present at the Leerink Partners 7th Annual Global Healthcare Conference
By a News Reporter-Staff News Editor at Biotech Week Acorda Therapeutics, Inc. announced that Ron Cohen, M.D., Acorda's President and CEO, will present at the Leerink Global Healthcare Conference on Thursday, February 15 at 1:30pm EST. A live audio webcast of the presentation can be accessed under "Investor Events" in the Investor section of the
2/21/18 - Aerie Pharmaceuticals Announces Appointment of John LaRocca as General Counsel
DURHAM, N.C.- Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced the appointment of John LaRocca as General Counsel, reporting to Vicente Anido,
2/21/18 - AIDS Healthcare Foundation to Sound Alarm That Important Lifesaving Drug Program Is Under Attack
AIDS Healthcare Foundation will sound an alarm at a San Diego press conference Wednesday that a nationwide drug pricing program vital to the country s health care safety net and its HIV/AIDS response is under attack under the guise of reform. The press conference takes place Wednesday, February 21 at 10:30am in the Pointe Room at the
2/21/18 - Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 56354
By a News Reporter-Staff News Editor at Biotech Week Akebia Therapeutics, Inc., a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor, granted nine newly-hired employees options to purchase an aggregate of 53,550 shares of Akebia's common stock on...
2/21/18 - Alder BioPharmaceuticals to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial and Operating Results
BOTHELL- Alder BioPharmaceuticals, Inc., a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will report its fourth quarter and year-end 2017 financial and operating results after the close of U.S. financial markets on Monday, February 26, 2018. Alder management will
2/21/18 - Aldeyra Therapeutics Selected for Podium Presentation of Phase 2a Dry Eye Disease Results at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Aldeyra Therapeutics, Inc., a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, today announced that the results of the Phase 2 a clinical trial of topical ocular reproxalap in dry eye disease were selected for podium presentation at the 2018 Association for Rese
2/21/18 - Amneal Introduces Memantine Hydrochloride Extended-Release Capsules, Generic for Namenda XR
The product is manufactured here in the United States in the company's recently expanded Brookhaven, New York facility. Amneal Pharmaceuticals LLC, a privately-held company headquartered in Bridgewater, New Jersey, is one of the largest and the fastest growing generics pharmaceutical manufacturers in the United States. Amneal Pharmaceuticals LLC an
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement